Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
As of close of business last night, Tarsus Pharmaceuticals Inc’s stock clocked out at $58.77, up 2.49% from its previous closing price of $57.34. In other words, the price has increased by $2.49 from its previous closing price. On the day, 0.56 million shares were traded. TARS stock price reached its highest trading level at $59.51 during the session, while it also had its lowest trading level at $56.25.
Ratios:
To gain a deeper understanding of TARS’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.21 and its Current Ratio is at 5.26. In the meantime, Its Debt-to-Equity ratio is 0.22 whereas as Long-Term Debt/Eq ratio is at 0.22.
On November 20, 2023, Goldman started tracking the stock assigning a Neutral rating and target price of $19.Goldman initiated its Neutral rating on November 20, 2023, with a $19 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Sep 24 ’25 when Azamian Bobak R. sold 6,000 shares for $55.37 per share. The transaction valued at 332,220 led to the insider holds 812,106 shares of the business.
Bobak Azamian Living Trust bought 6,000 shares of TARS for $332,208 on Sep 24 ’25. On Sep 08 ’25, another insider, LINK WILLIAM J PHD, who serves as the Director of the company, sold 27,116 shares for $57.00 each. As a result, the insider received 1,545,612 and left with 143,332 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TARS now has a Market Capitalization of 2480922880 and an Enterprise Value of 2172226048. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.40 while its Price-to-Book (P/B) ratio in mrq is 7.46. Its current Enterprise Value per Revenue stands at 7.35 whereas that against EBITDA is -22.529.
Stock Price History:
The Beta on a monthly basis for TARS is 0.82, which has changed by 0.7341399 over the last 52 weeks, in comparison to a change of 0.16766965 over the same period for the S&P500. Over the past 52 weeks, TARS has reached a high of $59.78, while it has fallen to a 52-week low of $31.73. The 50-Day Moving Average of the stock is 12.63%, while the 200-Day Moving Average is calculated to be 21.60%.
Shares Statistics:
It appears that TARS traded 654.35K shares on average per day over the past three months and 586350 shares per day over the past ten days. A total of 42.21M shares are outstanding, with a floating share count of 38.61M. Insiders hold about 8.53% of the company’s shares, while institutions hold 107.61% stake in the company. Shares short for TARS as of 1757894400 were 7634147 with a Short Ratio of 11.67, compared to 1755216000 on 7339962. Therefore, it implies a Short% of Shares Outstanding of 7634147 and a Short% of Float of 18.7.
Earnings Estimates
A comprehensive evaluation of Tarsus Pharmaceuticals Inc (TARS) is underway, with the input of 4.0 analysts contributing to its current rating.The consensus estimate for the next quarter is -$0.03, with high estimates of $0.02 and low estimates of -$0.14.
Analysts are recommending an EPS of between -$1.44 and -$1.56 for the fiscal current year, implying an average EPS of -$1.5. EPS for the following year is $0.03, with 3.0 analysts recommending between $1.39 and -$2.15.
Revenue Estimates
In. The current quarter, 6 analysts expect revenue to total $113.05M. It ranges from a high estimate of $118.92M to a low estimate of $109.93M. As of. The current estimate, Tarsus Pharmaceuticals Inc’s year-ago sales were $48.12MFor the next quarter, 6 analysts are estimating revenue of $131.67M. There is a high estimate of $137.26M for the next quarter, whereas the lowest estimate is $124.24M.
A total of 7 analysts have provided revenue estimates for TARS’s current fiscal year. The highest revenue estimate was $437.18M, while the lowest revenue estimate was $415.16M, resulting in an average revenue estimate of $425.61M. In the same quarter a year ago, actual revenue was $182.95MBased on 6 analysts’ estimates, the company’s revenue will be $607.94M in the next fiscal year. The high estimate is $715.08M and the low estimate is $464.91M.
